Abraxane Combination Improves Survival In Treatment-Naïve Metastatic Disease
Avastin Increases Overall Survival 3.7 Months
First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma
Phase III Trial of ThermoDox Fails to Meet Primary Endpoint
Neulasta Reduces Incidence Of Febrile Neutropenia
Tivozanib Does Not Improve OS Compared to Sorafenib
In Surgery vs Radiotherapy, Outcome Differences Equalize After 15 Years Follow-up
Genomic Test More Accurate In Predicting Metastasis Than PSA, Tumor Stage & Grade
Protein May Link Obesity To Cancer Aggressiveness
“Triple-Negative” Should Be Split Into Subtypes, Say Researchers
NCI CTEP Approved Trials For the Month of February
Avastin Combination Approved For Metastatic Colorectal Cancer
FDA Grants Priority Review To Two Drugs in NSCLC
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure